Cargando…
Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome
BACKGROUND: Germ-line mutations of the TP53 gene are known to cause Li-Fraumeni syndrome, an autosomal, dominantly inherited, high-penetrance cancer-predisposition syndrome characterized by the occurrence of a variety of cancers, mainly soft tissue sarcomas, adrenocortical carcinoma, leukemia, breas...
Autores principales: | Taja-Chayeb, Lucia, Vidal-Millán, Silvia, Gutiérrez-Hernández, Olga, Trejo-Becerril, Catalina, Pérez-Cárdenas, Enrique, Chávez-Blanco, Alma, de la Cruz-Hernández, Erick, Dueñas-González, Alfonso |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806269/ https://www.ncbi.nlm.nih.gov/pubmed/20017945 http://dx.doi.org/10.1186/1477-7819-7-97 |
Ejemplares similares
-
The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype
por: Ruijs, Marielle WG, et al.
Publicado: (2009) -
Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromes
por: Frebourg, Thierry, et al.
Publicado: (2020) -
Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells
por: Pérez-Cárdenas, Enrique, et al.
Publicado: (2018) -
DNA Methylation-Independent Reversion of Gemcitabine Resistance by Hydralazine in Cervical Cancer Cells
por: Candelaria, Myrna, et al.
Publicado: (2012) -
A Novel Variant in the TP53 Gene Causing Li–Fraumeni Syndrome
por: Papadimitriou, Dimitrios T., et al.
Publicado: (2023)